Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: Re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept

Rheumatology

Volumn 47, Issue 7, 2008, Pages 1044-1050

  Cole, J C ^a   Li, T ^b   Lin, P ^a   Maclean, R ^b   Wallenstein, G V ^a  

^a QualityMetric Incorporated   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Abatacept; Job loss; Medical expenditure; Quality of life; Rheumatoid arthritis

Indexed keywords

ABATACEPT; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COST; DRUG TREATMENT FAILURE; EFFECT SIZE; HEALTH CARE COST; HOSPITAL CHARGE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; TREATMENT OUTCOME; UNEMPLOYMENT; WORK DISABILITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HEALTH CARE COSTS; HEALTH STATUS INDICATORS; HUMANS; IMMUNOCONJUGATES; MALE; METHOTREXATE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; UNEMPLOYMENT; UNITED STATES;

EID: 45749156006     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken141     Document Type: Article

References (31)

1. Cole JC, Motivala SJ, Khanna D et al. Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index. Arthritis Rheum 2005;53:536-42.
2. Hazes JM, Geuskens GA, Burdorf A. Work limitations in the outcome assessment of rheumatoid arthritis. J Rheumatol 2005;32:980-2.
3. WHO. International classification of functioning, disability, and health: ICF http://www.whoint/classifications/icf/en/, 2001. (1 December 2007, date last accessed).
4. Verstappen SM, Bijlsma JW, Verkleij H et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
5. Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med 2006;56:18-27.
6. Yelin E, Murphy L, Cisternas MG et al. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum 2007;56:1397-407.
7. Yelin E. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates. J Rheumatol 1996;44(Suppl):47-51.
8. Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990;16:513-37.
9. Wolfe F. The burden of rheumatoid arthritis. Am J Manage Care 1999;S859.
10. Cohen JW, Monheit AC, Beauregard KM et al. The Medical Expenditure Panel Survey: A national health information resource. Inquiry 1996;33:373-89.
11. Michaud K. Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62.
12. Bjomer JB, Wallenstein GV, Martin MC et al. Interpreting score differences in the SF-36 vitality scale: Using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 2007;23:731-9.
13. Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years'follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002;61:335-40.
14. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108-17.
15. Emery P. The therapeutic potential of costimulatory blockade with CTLA41g in rheumatoid arthritis. Expert Opin Investig Drugs 2003;12:673-81.
16. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006;144:865-76.
17. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
18. Russell AS, Wallenstein GV, Li T et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 2007;66:189-94.
19. Westhovens R, Cole JC, Li T et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology 2006;45:1238-46.
20. Ware JE Jr, Bjorner JB, Kosinski M. SF-36 health survey: Manual and interpretation guide, 2nd edn. Lincoln, RI: QualityMetric, Inc., 2007.
21. Ware JE Jr, Kosinski M, Bjorner JB et al. User's manual for the SF-36 health survey (Version 2), 2nd edn. Lincoln, RI: QualityMetric, Inc., 2006.
22. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
23. Ware JE Jr, Kosinski M. SF-36 physical & mental health summary scales: A manual for users of version 1, 2nd edn. Lincoln, RI: QualityMetric, Inc., 2001.
24. Fleishman JA, Cohen JW, Manning WG, Kosinski M. Using the SF-12 health status measure to improve predictions of medical expenditures. Med Care 2006;44:154-63.
25. Hombrook MC, Goodman MJ. Assessing relative health plan risk with the RAND-36 health survey. Inquiry 1995;32:56-74.
26. Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. J Am Med Assoc 1989;262:907-13.
27. Tabachnick BG, Fidell LS. Using multivariate statistics, 5th edn. New York: Pearson Education, 2007.
28. Ware JE Jr, Keller SD. Interpreting general health measures. Quality of life and pharmacoeonomics in clinical trials. Philadelphia, PA: Lippincott-Raven Publishers, 1995.
29. FDA, DHHS. Review of BLA Submission 99-0128 Infliximab 9REMICADE) for signs and symptoms of rheumatoid arthritis. http://www.fdagov/cder/ biologics/review/inficen 111099r4.pdf,1999, (28 November 2007, date last accessed).
30. ACR Subcomittee on AR Guideline. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
31. Iversen GR. Bayesian statistical inference. Newbury Park, CA: Sage, 1984.